SCHEMBL2990778

SCHEMBL2990778

O=C(O)CNS(=O)(=O)c1ccc(F)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 3/20 0.67
GAA P10253 2/20 0.67
MMP12 P39900 1/20 0.67
LMNA P02545 3/20 0.66
MEP1B Q16820 1/20 0.64
MMP2 P08253 2/20 0.63
MMP9 P14780 2/20 0.63
MMP13 P45452 2/20 0.63
MMP3 P08254 1/20 0.63
MMP7 P09237 1/20 0.63
KMT2A Q03164 5/20 0.59
MEN1 O00255 4/20 0.59
ALDH1A1 P00352 3/20 0.59
HPGD P15428 1/20 0.59
HSD17B10 Q99714 1/20 0.59
APEX1 P27695 1/20 0.58
PKM P14618 1/20 0.58
SMN1; SMN2 Q16637 2/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4832336 0.85 MEN1 (0.62) LMNAKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL7522811 0.85 LMNA (0.52) MMP1GAAMMP12LMNAMEP1B
SCHEMBL2570058 0.84 MEP1B (0.62) MMP1GAALMNAMEP1BMMP2
SCHEMBL6619767 0.84 MEP1B (0.62) MMP1GAALMNAMEP1BMMP2
SCHEMBL6850069 0.84 MEP1B (0.62) MMP1GAALMNAMEP1BMMP2
SCHEMBL359770 0.82 MMP1 (0.79) MMP1GAAMMP12MMP2MMP9
SCHEMBL2947860 0.82 LMNA (0.82) GAALMNAMEP1BKMT2AMEN1
SCHEMBL23014361 0.82 KAT6A (0.58) MMP1GAAMMP12LMNAMEP1B
SCHEMBL760439 0.81 MMP1 (0.67) MMP1GAAMMP12LMNAMMP2
SCHEMBL19392592 0.81 MMP1 (0.67) MMP1GAAMMP12MEP1BMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190201414-A1 INHIBITOR OF HEME DEGRADATION FOR USE TO IMPROVE ANTIBIOTIC TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTION THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) 2019-07-04 US disclosed
US-8492437-B2 4-substituted phenoxyphenylacetic acid derivatives ARRAY BIOPHARMA INC. (US) 2013-07-23 US disclosed
US-8450368-B2 Heme oxygenase inhibitors, screening methods for heme oxygenase inhibitors and methods of use of heme oxygenase inhibitors for antimicrobial therapy UNIVERSITY OF MARYLAND, BALTIMORE (US) 2013-05-28 US disclosed
US-8450368-B2 Heme oxygenase inhibitors, screening methods for heme oxygenase inhibitors and methods of use of heme oxygenase inhibitors for antimicrobial therapy UNIVERSITY OF MARYLAND, BALTIMORE (US) 2013-05-28 US disclosed
EP-2057115-B9 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES ARRAY BIOPHARMA INC (US) 2012-12-26 EP disclosed
EP-2057115-B1 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES ARRAY BIOPHARMA INC (US) 2012-10-03 EP disclosed
US-20120202854-A1 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES ARRAY BIOPHARMA INC. (US) 2012-08-09 US disclosed
US-8183289-B2 4-substituted phenoxyphenylacetic acid derivatives ARRAY BIOPHARMA INC. (US) 2012-05-22 US disclosed
US-20100173955-A1 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES ARRAY BIOPHARMA INC. (US) 2010-07-08 US disclosed
US-20100081661-A1 HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY UNIVERSITY OF MARYLAND, BALTIMORE (US) 2010-04-01 US disclosed
US-20020028797-A1 N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists AMERICAN HOME PRODUCTS CORPORATION 2002-03-07 US disclosed
WO-2002006274-A1 N-(4-SULFONYLARYL)CYCLYLAMINE-2-HYDROXYETHYLAMINES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS WYETH (US) 2002-01-24 WO disclosed
US-6297247-B1 Sulfonamide inhibitors of matrix metalloproteinases WARNER-LAMBERT COMPANY 2001-10-02 US disclosed
US-6153612-A Sulfonamide inhibitors of matrix metalloproteinases WARNER-LAMBERT COMPANY (US) 2000-11-28 US disclosed
US-6087359-A A MATRIX METALLOPROTEASE ENZYME INHIBITOR PHARMACIA CORPORATION 2000-07-11 US disclosed
EP-0977745-A1 THIOARYL SULFONAMIDE HYDROXAMIC ACID COMPOUNDS MONSANTO COMPANY (US) 2000-02-09 EP disclosed
US-5977141-A Sulfonamide inhibitors of matrix metalloproteinases WARNER-LAMBERT COMPANY (US) 1999-11-02 US disclosed
EP-0874836-A1 SULFONAMIDE INHIBITORS OF MATRIX METALLOPROTEINASES WARNER-LAMBERT COMPANY (US) 1998-11-04 EP disclosed
WO-1998039313-A1 THIOARYL SULFONAMIDE HYDROXAMIC ACID COMPOUNDS MONSANTO COMPANY (US) 1998-09-11 WO disclosed
WO-1997019068-A1 SULFONAMIDE INHIBITORS OF MATRIX METALLOPROTEINASES WARNER-LAMBERT COMPANY (US) 1997-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173955-A1 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES CD22, HRH2, CD74 MMP1 4491/4885GAA 2523/4885MMP12 3161/4885
US-20100081661-A1 HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY HMOX1, HMOX2, PPOX MMP1 782/4885GAA 2000/4885MMP12 163/4885
US-20190201414-A1 INHIBITOR OF HEME DEGRADATION FOR USE TO IMPROVE ANTIBIOTIC TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTION HMOX1, HMOX2, PPOX MMP1 732/4885GAA 504/4885MMP12 124/4885
US-20120202854-A1 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES CD22, HRH2, CD74 MMP1 4491/4885GAA 2523/4885MMP12 3161/4885
US-20020028797-A1 N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists ADRB3, ADRB1, ADRB2 MMP1 4605/4885GAA 2167/4885MMP12 4692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.